MeSH D000077277 - esophageal squamous cell carcinoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D000077277:
Esophageal squamous cell carcinoma
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Beigene | Tislelizumab | Tevimbra | 2024-03-13 | |||
| Novartis | Tislelizumab | Tevimbra | 2023-09-15 |
Clinical Trials
Historical Success Rate
Phase 1
74%26/35
Phase 2
39%17/44
Phase 3
0%0/27
Approved: 0Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use